# Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention

> **NCT04571580** · PHASE3 · TERMINATED · sponsor: **Ge Junbo** · enrollment: 36 (actual)

## Conditions studied

- Acute ST-segment Elevation Myocardial Infarction

## Interventions

- **DRUG:** Normal Saline
- **DRUG:** Reteplase Injection 9mg
- **DRUG:** Reteplase Injection 18mg

## Key facts

- **NCT ID:** NCT04571580
- **Lead sponsor:** Ge Junbo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-01
- **Primary completion:** 2023-01-31
- **Final completion:** 2023-01-31
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** The study enrollment is slow due to the pandemic.
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04571580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04571580, "Effect of Low-dose Intracoronary Reteplase on Myocardial Infarct Size During Primary Percutaneous Coronary Intervention". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04571580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*